Brainsgate is a medical device company committed to developing a novel treatment modality, electrical SPG stimulation. This platform technology has been shown to increase blood flow to the brain and as a result has broad potential for treating central nervous system disorders. BrainsGate is currently focusing on:

1. Improve the outcome of patients suffering from ischemic stroke, in a 24 hour window after onset of symptoms.

2. Enable drug delivery into the central nervous system, overcoming the blood-brain barrier, and opening a window for addressing currently untreatable CNS diseases.

Focus: ISS BrainsGate's product for increasing BBB permeability and improving ischemic stroke outcome read more

Focus: Stroke The leading cause of adult long-term disability and the third leading cause of death read more